Skip to main content

Rare Disease Congressional Caucus

Below is a message from NORD I'm passing along.

Rare Disease Day Partner



Ask Your Congressional Rep to Join New Rare Disease Caucus






Thank you for signing up as a Rare Disease Day Partner or Ambassador! Here is one of the easiest, but most important, things you can do to support Rare Disease Day 2011:






Write Your Reps Campaign






Many of you know that NORD and its advocacy partners have worked with members of the U.S. Congress to establish a Rare and Neglected Diseases Congressional Caucus and that Congressman Joe Crowley (D-NY) has agreed to co-chair it. The launch of this Caucus was originally announced at the NORD Gala in May. However, because of the November elections and following lame duck session, promotion of the Caucus has been low-key to date.






Now it's time to bump it up a notch. It's time for all of us to urge our Congressional Representatives to join the Caucus. As one of our primary Rare Disease Day 2011 activities, NORD is asking all our Partners and Ambassadors to join us in a Write Your Reps Campaign in support of the Rare and Neglected Diseases Caucus.






How to Do It






Check the list of Caucus members on the NORD website to see if your Representative's name is there. Then click on the following link and enter your zipcode to access an online form that will allow you to send an email directly to your Representative: https://writerep.house.gov/writerep/welcome.shtml. (This will also allow you to confirm who your current Representative is, if you've forgotten.)






In your email, you should ask your Representative to contact Nicole Cohen at nicole.cohen@mail.house.gov to join the Rare and Neglected Diseases Caucus. (Nicole is in Rep. Crowley's office.) Tell your Representative that:






•Rare diseases are important to you because you (or a family member or friend) have one.


•Most rare diseases have a significant impact on the lives of those affected. (Feel free to briefly describe your own experiences.)


•Most rare diseases still have no treatment. Of the 6,800 listed on the NIH website, only about 200 have FDA-approved treatments.


•Individuals and families affected by rare diseases feel alone and forgotten by our nation's healthcare system, and often have to fight their own battles to obtain needed treatment and services.


•The word "rare" is misleading. Nearly 30 million Americans have rare diseases, and we are lifting our voices as a group to ensure that our message is heard.


•The Rare and Neglected Diseases Caucus will provide a forum through which members of the House of Representatives can discuss issues that are important to many of their constituents.


Your Email is Important!






Sometimes people think their voices won't be heard when they contact members of Congress. This isn't true. NORD's public policy team reminds us again and again that every voice is heard, and that the messages constituents send to their Congressional Representatives are taken seriously. Members of Congress know that if you care enough to write, you care enough to vote. Your message will be heard.






How Can the Caucus Help?






A Caucus will provide a specific forum for the exchange of ideas and information related to rare diseases. With a robust membership and a policy agenda, it can drive positive, meaningful legislation. A determined and bipartisan Rare and Neglected Diseases Caucus can result in a Congress that is better educated about this constituency and more capable of addressing the issues.






This is an opportunity for every one of us to help. Please write your Representative today and ask him or her to join the Caucus. Or, if your Representative is already a member of the Caucus, please write today to thank him or her for joining.






Remember: Your Representative knows that if you care enough to write, you care enough to vote! Your message will be heard.














Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria